Want to join the conversation?
$EBS signed a multi-year contract with the Biomedical Advanced Research and Development Authority, for the advanced development and delivery of NuThrax, $EBS' next generation anthrax vaccine candidate. The contract is valued at up to approx. $1.6Bil & consists of a 5-year base period of performance valued at approx. $200MM to develop NuThrax.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.